Targeted Delivery of Panitumumab-Scaffold Bosutinib-Encapsulated Polycaprolactone Nanoparticles for EGFR-Overexpressed Colorectal Cancer

Abstract

Aims: Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib (BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials & methods: Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used to analyze nanoparticles. Results: According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential. An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively. Conclusion: Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.

Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers

“…Its molecular targeting often enhances drug antitumor activity [ 231 ]. The epidermal growth factor (EGF), due to its specific and strong binding to the receptor, was successfully used as a functionalization strategy in colon cancer drug delivery [ 232 , 233 ], by exploiting, for example, PLGA nanoparticles [ 234 ] or lipid-based systems [ 235 , 236 ]. Liszbinski et al proved that gold carriers coated with anti-EFGR stopped cancer cells [ 237 ].…”